Log In
BCIQ
Print this Print this
 

Pharmalgen

  Manage Alerts
Collapse Summary General Information
Company ALK-Abello A/S
DescriptionHymenoptra venom/venom protein
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsTreat IgE-mediated bee and wasp venom allergy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$81.4M

$40.7M

$40.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/28/2011

$81.4M

$40.7M

$40.7M

Get a free BioCentury trial today